An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety and Sustained Efficacy of Denosumab (AMG162) in the Treatment of Postmenopausal Osteoporosis

Published: 01-11-2007
Last updated: 08-05-2024

To describe the safety and tolerability of up to 5 years denosumab administration as measured by adverse event monitoring, immunogenicity, and safety laboratory parameters in subjects who previously received denosumab.

Ethical review	-
Status	Will not start
Health condition type	Bone disorders (excl congenital and fractures)
Study type	Interventional

Summary

ID

NL-OMON30869

Source
ToetsingOnline

Brief title
Study to evaluate Denosumab in the treatment of postmenopausal osteoporosis

Condition

- Bone disorders (excl congenital and fractures)

Synonym
Postmenopausal osteoporosis

Research involving
Human

Sponsors and support

Primary sponsor: Amgen
Source(s) of monetary or material Support: Amgen

Intervention

Keyword: Bone Mineral Density, Osteoporosis, Vertebral fracture

Outcome measures

Primary outcome

Safety monitoring, including adverse event incidence, serious adverse event incidence, changes in safety laboratory analytes (serum chemistry, hematology) and subject incidence of anti-denosumab antibody formation in subjects previously treated with denosumab who receive up to 5 years of denosumab administration

Secondary outcome

- BMD of the lumbar spine, total hip and in a subset of subjects distal radius at month 12 and month 24

- Vertebral fractures at month 24 and non-vertebral fractures at month 12 and month 24

- Bone Turnover Markers (Type 1 CTX, iPTH, RANKL, OPG, BALP, P1NP) in a subset of subjects at Day 10, month 6, month 12 and month 24

- Serum calcium values at Day 10

- Bone histology in a subset of subjects previously treated with denosumab who receive up to 5 years of denosumab administration

- Safety monitoring, including adverse event incidence, serious adverse event incidence, changes in safety laboratory analytes (serum chemistry, hematology),

and subject incidence of anti denosumab antibody formation in subjects

previously treated with placebo who receive up to 2 years of denosumab

administration

Study description

Background summary

Protocol 20030216 is an ongoing double blind, placebo-controlled, Phase 3 study to evaluate denosumab at a dose of 60 mg administered SC every 6 months, in the treatment of post menopausal osteoporosis. All subjects who complete the 20030216 protocol, remain on investigational product, and meet the inclusion/exclusion criteria will be invited to participate in the 20060289 study to receive open-label denosumab 60mg every 6 months for two years, regardless of their prior randomization to placebo or denosumab.

Study objective

To describe the safety and tolerability of up to 5 years denosumab administration as measured by adverse event monitoring, immunogenicity, and safety laboratory parameters in subjects who previously received denosumab.

Study design

Subjects who have completed the 20030216 study will be eligible to participate in this study, if they did not missed two or more investigational product doses and did complete the month 36 visit. Subjects must be dosed within 28 days of the 20030216 study month 36 visit.
Subjects will be dosed every 6 months (i.e. at Day 1, 6 months, 12 months and 18 months) and followed over a 24 month period.

Intervention

Subjects will receive a 60mg SC injection of denosumab every 6 months for 24 months (at Day 1, 6 months, 12 months and 18 months)

Study burden and risks

Load for the patients:
The following procedures will be performed per the schedule outlined in Appendix A: physical exam, vital signs, DXA, lateral radiographs, hematology,

serum chemistry, serum calcium and albumin, and anti-denosumab antibody levels. Adverse events, clinical fractures, and concomitant medications will be recorded throughout study participation.

Risk:
In patients receiving denosumab, the most frequent adverse events occurring very commonly (>=10%) in clinical trials included upper respiratory tract infection or inflammation (such as sore throat); nausea, headache, pain in joints, back and extremities, urinary tract infection, constipation, bone pain, weakness, fatigue, flu, high blood pressure, upset stomach, vomiting, rheumatoid arthritis (in patients with rheumatoid arthritis only) and diarrhea. A short term decrease in blood calcium levels below normal has been observed in some subjects, and occasionally has been associated with symptoms. Osteonecrosis of the jaw has been reported in patients treated with bisphosphonates. The potential risk of osteonecrosis of the jaw in patients receiving denosumab is unknown. The effect of denosumab on bone resorption appears fully reversible and discontinuing the drug can lead to reversal of the gains made in bone density. Development of antibodies to denosumab in patients has been uncommon. To date, no clinical effects have been observed in patients who have developed antibodies to denosumab.

Contacts

Public
Amgen

Minervum 7061
4800DH Breda
NL
Scientific
Amgen

Minervum 7061
4800DH Breda
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

- Subjects must sign the informed consent before any study specific procedures are performed and agree to receive denosumab 60mg SC injection every 6 months.
- Subjects must not have discontinued investigational product during the 20030216 study and must have attended the 20030216 study month 36 visit

Exclusion criteria

- Permanently non-ambulatory subjects (use of an assistive device e.g. cane, walker etc is permitted)
- Missed two or more investigational product doses during the 20030216 study
- Any disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or comply with study procedures
- Developed sensitivity to mammalian cell derived drug products during the 20030216 study
- Unable to tolerate calcium supplementation during the last 6 months of participation in the 20030216 study (between the month 30 and month 36 20030216 study visits)
- Receiving any investigational product other than denosumab
- Current use of the following osteoporosis agents: bisphosphonates, calcitonin, fluoride, parathyroid hormone, selective estrogen receptor modulators, systemic oral or transdermal estrogen (except vaginal preparations and estrogen creams which are acceptable), strontium or tibolone.
- For bone biopsy sub-study subjects only: known or suspected sensitivity or contraindication to tetracycline derivatives

Study design

Design

Study phase:	3
Study type:	Interventional
Masking:	Open (masking not used)
Control:	Uncontrolled

Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Will not start
Start date (anticipated):	19-10-2007
Enrollment:	62
Type:	Anticipated

Medical products/devices used

Product type:	Medicine
Brand name:	Not Applicable
Generic name:	Denosumab

Ethics review

Not available

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EudraCT	EUCTR2007-001041-17-NL
ClinicalTrials.gov	NCTnummernognietbekend
CCMO	NL18474.091.07